The use of almost every antibiotic increases the chances of Clostridioides difficile infection, and that includes the drugs that are used to treat C diff, a study states.
When it comes to what circumstances help breed Clostridioides difficile infection (CDI), there are some that could be called the usual suspects. They include increased age, hospitalization, use of proton pump inhibitors, and use of antibiotics, according to a recent study out of Pakistan. That study, published in Cureus,1 looked at data from 200 patients diagnosed with
C difficile–associated diarrhea (CDAD) at a tertiary care hospital in Pakistan between June 2020 and March 2021, along with 200 patients without CDAD in a control group.
“Identifying and addressing the risk factors associated with CDI will help [reduce] the incidence of infection and associated complications,” the authors, led by Aarzoo Gupta of Vardhman Mahavir Medical College and Safdarjung Hospital in Faridabad, India, wrote.
The study included detailed histories of patients’ use of treatments (antibiotics, proton pump inhibitors, and histamine 2 receptor antagonists), previous CDI diagnoses, and hospitalization in the past 30 days. Investigators also noted patients’ body mass index (BMI) and comorbidities including diabetes, chronic kidney disease (CKD), hypertension, and malignancy.
In the case group, 31 patients were older than 65 (15.5%), compared with 16 (8%) in the control group (OR [odds ratio], 2.10 [1.11-3.99]; P = .02). “This age group is not only termed as a risk factor for CDI but such patients also demonstrate poor prognosis, leading to increased clinical severity and death rates,” the authors wrote.
Patients with CDI also had significantly higher hospitalization (25.5% vs 6%; OR, 5.36 [2.75-10.42]; P < .0001), use of proton pump inhibitors in past 30 days (23.0% vs 10.5%; OR, 2.54 [1.45-4.45]; P = .001), and use of antibiotics in the past 30 days (36.0% vs 10.5%; OR, 4.76 [2.80-8.19]; P < .0001).
“Studies have suggested that almost every antibiotic results in an increased chance of developing CDI,” the authors wrote. “This also includes the drugs that are used to treat CDI, namely metronidazole and vancomycin.”
Other risk factors included a BMI above 25 kg/m2 (31% vs 21%; OR, 1.69 [1.07-2.65]; P = .02), diabetes (27% vs 16%; OR, 1.94 [1.18-2.17]; P = .008), CKD (19% vs 9.5%; OR, 2.23 [1.23-4.03]; P = .007), and malignancy (6% vs 2%; OR, 3.12 [0.99-9.86]; P = .05).
“Given the findings [above], our study suggests that the use of acid-suppressive agents should be carefully considered, and the over-the-counter availability of these agents should be discouraged,” the authors wrote. “This would help the doctors to keep a check in order to avoid overdose. Moreover, hygiene practices, such as hand washing practices, sterilizing used [equipment] at the hospital, using clean medical devices, etc, should be adopted to avoid infection risk. Maximum management of antibiotic intake should also be taken into consideration.”
CDI is the leading cause of health care–associated infections, causing about a half million infections and $1 billion in health care costs each year. Although CDI is often associated with health care settings, a recent study by investigators at the University of Houston found that the bacterium is prevalent in a variety of settings, including on 45% of shoe soles.2 Healthy people can carry CDI without illness or symptoms.
This article originally appeared in Contagion®3
References:
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.